Elevance Health Reaffirms 2026 Earnings Guidance

What Happened

• Elevance Health, Inc. filed an 8‑K (Regulation FD disclosure) on September 10, 2026, saying officers will speak with investors and analysts in the coming weeks and will reaffirm full‑year 2026 guidance.
• The company reaffirmed shareholders’ earnings guidance of at least $20.10 per diluted share for 2026, which includes approximately $6.90 per diluted share of net unfavorable items. Excluding those items, adjusted shareholders’ earnings are expected to be at least $27.00 per diluted share.
• The company also reaffirmed full‑year 2026 benefit expense ratio guidance of 90.2%, plus or minus 50 basis points. The guidance excludes any additional adjustment items beyond those reported in Elevance’s Q2 2026 earnings.

Key Details

• Filed: Form 8‑K (Regulation FD disclosure) on September 10, 2026.
• Shareholders’ earnings guidance: ≥ $20.10 per diluted share for FY2026.
• Adjusted shareholders’ earnings (ex-net unfavorable items): ≥ $27.00 per diluted share.
• Benefit expense ratio guidance: 90.2% ± 50 basis points (range ~89.7%–90.7%).

Why It Matters

• This is a reaffirmation of guidance, not new results: management is telling investors they still expect to meet the previously announced 2026 targets. That can reduce uncertainty for shareholders relying on the company’s outlook.
• The split between reported shareholders’ earnings ($20.10) and adjusted earnings ($27.00) shows a sizable impact from the roughly $6.90 of net unfavorable items—important when comparing GAAP vs adjusted performance.
• The benefit expense ratio is a key operating metric for insurers; the guidance range gives investors a sense of expected claims and medical cost trends for 2026.